8,096 results on '"Kantarjian, Hagop M."'
Search Results
2. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin
3. SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia
4. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
5. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL
6. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm
7. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia
8. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
9. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
10. Management of chronic myeloid leukemia in 2023 – common ground and common sense
11. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
12. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
13. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)
14. Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia
15. What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia
16. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia
17. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia
18. Revisiting six established practices in the treatment of chronic myeloid leukaemia
19. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
20. A global study for acute myeloid leukemia with RARG rearrangement
21. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
22. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
23. SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches
24. Leukemia Therapy-A Look Into the Future
25. Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
26. Minimal or Measurable Residual Disease in Acute Lymphoblastic Leukemia
27. Frontline Therapy of Newly Diagnosed Acute Lymphoblastic Leukemia
28. Management of Relapsed/Refractory Acute Myeloid Leukemia
29. Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.
30. Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia (AML) study.
31. In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.
32. FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.
33. Impact of JAK2 allele burden on MF outcome in the era of ruxolitinib.
34. Outcomes of patients with bone marrow fibrosis in de novo and secondary acute myeloid leukemia.
35. A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.
36. Ponatinib‐review of historical development, current status, and future research
37. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
38. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib
39. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases
40. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
41. Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis
42. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
43. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL
44. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
45. NPM1‐mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage.
46. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
47. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.
48. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.
49. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage
50. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.